US approves first new Alzheimer’s drug in almost two decades

The decision was highly anticipated but also contentious, because an independent expert panel convened by the regulatory Food and Drug Administration last November found insufficient evidence of Aduhelm’s benefit and recommended against approval.

Read the full story: Read More